Results 21 to 30 of about 4,968,206 (256)

Disease Course After Anti-CD20 Discontinuation in Secondary Progressive Multiple Sclerosis-A Multicenter Long-Term Longitudinal Study. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Otto F, Kliushnikova D, Radlberger RF, Yasaroglu S, Moser T, Harrer A, Kratzer K, Hitzl W, Gradl C, Schmidauer M, Roth P, Hegen H, Wipfler P.   +12 more
europepmc   +2 more sources

T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis [PDF]

, 2010
Objectives: Prediction of long term clinical outcome in patients with primary progressive multiple sclerosis (PPMS) using imaging has important clinical implications, but remains challenging.
Polman, C., Barkhof, F., Montalban, X, CHARD D, Thompson, A, Polman, C, F. Barkhof, Chard, D, Samson, R., D. Miller, Bodini, B., A. Thompson, Samson, R, MONTALBAN X, R. Samson, Rovira, A, POLMAN C, KHALEELI Z, O. Ciccarelli, Filippi, M., N. De Stefano, Barkhof, F, BATTAGLINI, MARCO, B. Bodini, A. Rovira, Battaglini, M, Polman, C.H., Chard, D., CICCARELLI O., Miller, D., Rovaris, M, Battaglini, M., Thompson, A., De Stefano, N., X. Montalban, MILLER D, ROVARIS M, FILIPPI M, D. Chard, Khaleeli, Z, SAMSON R, ROVIRA A, THOMPSON A, Rovaris, M., De Stefano, N, Rovira, A., Z. Khaleeli, Bodini, B, BODINI B, M. Filippi, Miller, D, BARKHOF F, DE STEFANO, NICOLA, M. Rovaris, Montalban, X., Ciccarelli, O., Ciccarelli, O, Khaleeli, Z., M. Battaglini, C. Polman, Filippi, M, Rovira, Alex, Stefano, N. De, Rovaris, Marco, Thompson, Alan, De Stefano N, Battaglini M, FILIPPI , MASSIMO, Barkhof, Frederik, Polman, Chris, Montalban, Xavier, Ciccarelli, Olga, Miller, David, Filippi, Massimo, Khaleeli, Zhaleh, Chard, Declan, Filippi, M., Bodini, Benedetta, Samson, Rebecca   +78 more
core   +1 more source

Validity of apparent diffusion coefficient (ADC) value in diagnosis and follow-up of multiple sclerosis patients in different clinical subtypes

The Egyptian Journal of Radiology and Nuclear Medicine, 2018
Background: Multiple sclerosis (MS) is a chronic disease with a wide range of pathologic changes that modify the apparent diffusion coefficient (ADC) value.
Faten Fawzy Mohammed, Mohamed Hamdy Ismail   +1 more
doaj   +1 more source

Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome [PDF]

, 2004
Objectives: To develop a patient-based, disease-specific measure of the health impact of multiple sclerosis ( MS) for use in clinical trials and clinical practice. Data sources: People with MS.
Lamping, DL, R Fitzpatrick, Hobart, JC, Riazi, A, D Lamping, Fitzpatrick, R, Thompson, AJ, J Hobart, A Riazi, A Thompson   +9 more
core   +5 more sources

Progressive multiple sclerosis: latest therapeutic developments and future directions

Therapeutic Advances in Neurological Disorders, 2019
Multiple sclerosis (MS) is a chronic inflammatory condition of the central nervous system leading to demyelination and neurodegeneration. While the initial presentation is mostly characterized by a relapsing–remitting disease, patients often progress ...
Simon Faissner, Ralf Gold
doaj   +1 more source

Lipidomic UPLC-MS/MS Profiles of Normal-Appearing White Matter Differentiate Primary and Secondary Progressive Multiple Sclerosis

Metabolites, 2020
Multiple sclerosis (MS) is a neurodegenerative inflammatory disease where an autoimmune response to components of the central nervous system leads to a loss of myelin and subsequent neurological deterioration.
Petros Pousinis, Ines R. Ramos, M. Nicola Woodroofe, Laura M. Cole   +3 more
doaj   +1 more source

Imaging of repeated episodes of demyelination and remyelination in multiple sclerosis

NeuroImage: Clinical, 2014
Multiple sclerosis (MS) is characterized by the formation of demyelinating lesions in the white matter (WM). However, the timecourse of the evolution of healthy white matter into fully demyelinated lesions in MS is not well understood.
Robert A. Brown, Sridar Narayanan, Douglas L. Arnold   +2 more
doaj   +1 more source

Diffusion tensor imaging tractography reveals altered fornix in all diagnostic subtypes of multiple sclerosis

Brain and Behavior, 2020
Introduction Diffusion tensor imaging (DTI) has shown abnormalities of the fornix and other limbic white matter tracts in multiple sclerosis (MS), mainly focusing on relapsing‐remitting MS.
Diana Valdés Cabrera, Robert Stobbe, Penelope Smyth, Fabrizio Giuliani, Derek Emery, Christian Beaulieu   +5 more
doaj   +1 more source

Quantification of cerebral tissue volumes in multiple sclerosis: global and regional analysis [PDF]

, 2006
Brain atrophy has been reported in multiple sclerosis (MS). We addressed the question of GM and WM tissue loss in a large population of 597 patients with multiple sclerosis (MS) compared with 104 control subjects using a fully automated, operator ...
Prinster, Anna
core   +1 more source

Prioritizing progressive MS rehabilitation research: A call from the International Progressive MS Alliance [PDF]

, 2021
Cognition; Fatigue; MobilityCognición; Fatiga; MovilidadCognició; Fatiga; MobilitatBackground: People with multiple sclerosis (MS) experience myriad symptoms that negatively affect their quality of life.
Zackowski, Kathleen, Freeman, Jennifer, Centonze, Diego, Dalgas, Ulrik, Sastre Garriga, Jaume, Brichetto, Giampaolo, DeLuca, John   +6 more
core   +1 more source